Compare ADPT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | PRCT |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2019 | 2021 |
| Metric | ADPT | PRCT |
|---|---|---|
| Price | $16.15 | $30.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $16.60 | ★ $51.13 |
| AVG Volume (30 Days) | ★ 2.8M | 1.4M |
| Earning Date | 02-10-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $252,754,000.00 | ★ $299,907,000.00 |
| Revenue This Year | $50.81 | $48.30 |
| Revenue Next Year | $1.17 | $29.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 42.57 | ★ 50.07 |
| 52 Week Low | $5.96 | $27.80 |
| 52 Week High | $20.76 | $89.49 |
| Indicator | ADPT | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 40.19 |
| Support Level | $16.05 | $31.78 |
| Resistance Level | $16.82 | $32.94 |
| Average True Range (ATR) | 0.60 | 1.46 |
| MACD | -0.03 | -0.40 |
| Stochastic Oscillator | 42.26 | 3.09 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.